coplug
    Back to PCN explorer
    PCN reports · Core20PLUS5

    Hyndburn Rural PCN, Hyndburn · Health Inequalities Profile

    PCN U09057 · NHS Lancashire and South Cumbria Integrated Care Board · 7 GP practices

    Read the report

    This report is generated by Coplug's Healthcare Agent. Log in to ask further questions of it, add the spatial context, or create new enquiries to better understand and improve your Neighbourhood's Health

    01 / 15

    Board summary

    Key figures

    30,725

    Registered population

    59.2% aged 18–64

    20.4%

    Aged 65+

    ICB 20.0% · England 17.9%

    13.9%

    Ethnic minority (non-White)

    11.7% Asian · England 9.6%

    41.7%

    In IMD quintile 1

    ICB 30.6% · England 21.0%

    ~11,048

    Core20 residents (est.)

    Resident basis; registered basis ~13,765 · see page 3

    5,656

    Hypertension register

    +4.27% in 3 yrs · England +5.60%

    382

    SMI register

    36% of Hyndburn's

    813

    COPD register

    Reviews -4.16% in 3 yrs

    Forecast to 2030

    6,203

    Hypertension patients, 2030

    +547 on today

    71.1%

    QRISK ≥20% on statins, 2030

    +3.87pp over 3 yrs

    5.2%

    Cancer prevalence, 2030

    England 4.5%

    Three things the board should see

    58.1%
    Asthma reviews lag England after three-year fall.

    Annual asthma reviews reach 58.1% against 65.7% in England after falling 8.7% over 2023 to 2025, which may reflect recall capacity.

    52.3%
    Non-frail diabetes HbA1c control trails England.

    HbA1c control at or below 58 mmol/mol in non-frail diabetes is 52.3% (916 of 1,750 patients) versus 57.4% in England, suggesting recall needs.

    71.9%
    Hypertension treatment to target exceeds England.

    Hypertension treatment to target reaches 71.9% against 70.3% in England and 70.3% in the ICB, while diabetes with frailty HbA1c control reaches 86.2%.

    Sources & context

    PCN and practice-level primary care data; ICB and provider context on page 8

    Powered by Coplug · Page 1 of 15
    02 / 15

    Population, age and ethnicity

    Patients aged 65+ reach 20.4% alongside concentrated Asian populations across member practices

    Hyndburn Rural PCN plans services for 30,725 registered patients (practice lists sum to 30,728). Older patients aged 65+ make up 20.4% (6,255), exceeding Hyndburn (16.5%), the ICB (20.0%) and England (17.9%), while children aged 0–17 comprise 20.5% (6,287; Hyndburn 22.2%, ICB 19.6%, England 19.6%). Census resident data (not registered patients) indicates 11.7% Asian or Asian British residents, below Hyndburn (15.1%) but above the ICB (9.4%) and England (9.6%). This concentration reaches 64.6% at King Street Medical Ctr, 27.8% at Dr Bello's Surgery, and 26.3% at Dill Hall Surgery, against 2.7% at Higher Heys Surgery.

    Age profile

    0–1720.5%
    18–6459.2%
    65+20.4%

    65+: ICB 20.0%, England 17.9%

    Ethnicity

    White86.1%
    Asian11.7%
    Mixed1.3%
    Other0.6%
    Black0.3%

    Older people · falls rows are Hyndburn local-authority (LA) data, not PCN

    MeasureLocalNorth WestEnglandPeriod
    Falls admissions, 65+, per 100,000 (Hyndburn LA)1,9972,0711,9582024/25
    Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN)86.2%82.9%81.9%2024/25
    Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN)52.3%56.6%57.4%2024/25
    Falls admissions, 65 to 79, per 100,000 (Hyndburn LA)1,0991,0219552024/25
    Falls deaths, all ages, per 100,000 (Hyndburn LA)14.218.214.82022‑24
    Sources & context

    Census 2021; Fingertips falls and diabetes. Falls are local-authority data. Ethnic minority = 100% minus White

    Powered by Coplug · Page 2 of 15
    03 / 15

    Deprivation and Core20

    Core20 deprivation affects 41.7% of patients, spanning 67.8 percentage points between practices

    Across the PCN, 41.7% of registered patients live in Core20 areas, below Hyndburn (54.1%) but above the ICB (30.6%) and England (21.0%). Practice shares span 67.8 pp from 32.2% to 100.0%. Concentration is highest at King Street Medical Ctr (100.0%) and Dr Bello's Surgery (81.2%), while volume concentrates at The Weavers Practice (3,088) and Great Harwood Medical Group (3,067). Practice estimates sum to 13,765 registered patients, differing from the 11,048 resident estimate. Delivery requires whole-practice pathways for high-concentration surgeries alongside targeted recall lists for high-volume practices.

    % of patients in IMD quintile 1, by practice

    Dashed line: England 21.0% · right column: Core20 patients, registered basis

    King Street100.0% · 1,888 patients
    Dr Bello's81.2% · 1,935 patients
    Dill Hall79.4% · 2 patients
    Clayton Medical45.6% · 2,774 patients
    Higher Heys40.5% · 1,011 patients
    Weavers36.9% · 3,088 patients
    Great Harwood32.2% · 3,067 patients
    Sources & context

    Deprivation: Index of Multiple Deprivation, applied to registered patients

    Powered by Coplug · Page 3 of 15
    04 / 15

    PLUS groups and inclusion health

    PLUS groups and inclusion health

    382

    SMI register

    1.15% recorded prevalence

    268

    Learning disability register

    0.81% recorded prevalence

    31

    Care homes, 629 beds

    In the PCN catchment

    10.2%

    Provide unpaid care

    Hyndburn, Census 2021

    The PCN records 268 patients with learning disabilities (0.8%; Hyndburn 0.9%, ICB 0.6%, England 0.6%) and 382 on the severe mental illness register (1.1%; Hyndburn 1.3%, ICB 1.2%, England 1.0%), alongside 31 catchment care homes with 629 beds. With learning disability and severe mental illness prevalence above England, protecting annual health checks and primary care liaison for these vulnerable cohorts is an operational priority.

    Severe mental illness: physical health checks

    SMI BMI recording is 76.9% (England 82.1%, ICB 76.8%), while 12-month blood pressure checks reached 81.6% (England 83.4%, ICB 79.8%). Across the 382-patient severe mental illness register, physical monitoring trails England benchmarks.

    Sources & context

    QOF registers; Census 2021 carers; care homes and homelessness as supplied. Carers and homelessness are local-authority data

    Powered by Coplug · Page 4 of 15
    05 / 15

    Clinical focus: hypertension and lipids

    Clinical focus: hypertension and lipids

    5,656

    Hypertension register

    +4.27%

    Register growth, 3 yrs

    Hyndburn +2.89% · England +5.60%

    +2.07pp

    BP control, under 80

    ≤140/90 · +2.30pp aged 80+

    +547

    More patients by 2030

    Forecast 6,203 (18.56%)

    Hypertension case-finding and control

    Hyndburn Rural PCN records 5,656 patients on its hypertension register, a crude prevalence of 17.1% (Hyndburn 16.4%, ICB 17.2%, England 15.2%). Between 2023 and 2025, register growth of +4.3% trailed England (+5.6%) and the ICB (+6.3%), though exceeding Hyndburn (+2.9%). Blood pressure monitoring is 89.8% (Hyndburn 88.8%, ICB 89.0%, England 90.0%), and treatment to target reaches 71.9% (Hyndburn 70.1%, ICB 70.3%, England 70.3%). Across practices, prevalence ranges from 13.5% at King Street Medical Ctr to 19.0% at Great Harwood Medical Group. Although blood pressure control exceeds regional and national rates, slower register growth than England and lower prevalence at certain practices may indicate undetected hypertension, warranting targeted case finding.

    Lipids and statins

    For diabetes with history of CVD, statin therapy is 81.1% (Hyndburn 84.6%, ICB 84.1%, England 84.4%), after falling 0.4% over 2023 to 2025 (England +1.0%). For QRISK ≥ 20%, lipid-lowering therapy reaches 62.6% (Hyndburn 63.3%, ICB 61.4%, England 63.6%). Fewer high-risk patients receive lipid-lowering therapy than England rates imply, making secondary-prevention recall the priority.

    MeasureItemsCost / itemICBEnglandAnnual spend
    Lipid-modifying, 202680,012£1.90£1.64£1.86£152,023
    Cardiovascular (all), 2025111,314£3.09£3.38£3.33£343,960

    In 2026, lipid-modifying drugs accounted for 80,012 prescribed items at £1.90 per item (Hyndburn £1.64, ICB £1.64, England £1.86), which is £20,803 more than at NHS Lancashire and South Cumbria Integrated Care Board's unit cost. Spending more per item than the ICB indicates an opportunity to review formulary adherence across practices.

    Sources & context

    QOF hypertension register and BP control indicators; prescribing items and cost as supplied

    Powered by Coplug · Page 5 of 15
    06 / 15

    Clinical focus: respiratory, cancer register and children

    Clinical focus: respiratory, cancer register and children

    Respiratory

    −8.67%

    Asthma reviews, PCN 3-yr % change

    +4.44%

    Asthma reviews, England 3-yr % change

    −4.62%

    Asthma prevalence, PCN 3-yr % change

    Asthma prevalence is 7.6% (England 6.6%) across 2,372 patients, yet 12-month reviews fell 8.7% over 2023 to 2025 (England +4.4%) to 58.1% (England 65.7%), leaving about 990 patients unreviewed. Prescribing of asthma items for ages 5-19 reached 1,886 per 1,000 (England 1,488), whilst second-hand smoke recording for ages 6-19 is 69.4% (England 78.8%). COPD prevalence is 2.5% (England 1.9%), where reviews fell 4.2% over 2023 to 2025 (England +2.8%) to 73.8% (England 76.4%). These declines may reflect recall capacity, which an audit would test.

    Cancer register and children's immunisation

    Cancer register prevalence is 4.3% (1,437 patients; England 3.8%). In Q1 2025/26 childhood immunisations at age 5, MMR dose 1 reached 96.0% (England 91.7%) while dose 2 reached 90.7% (a 5.3 pp dose difference). The 4-in-1 pre-school booster reached 84.0% (ICB 85.2%), trailing 11 pp below the 95.0% target.

    Dashed line: 95% national coverage target · solid tick: England

    6-in-1 at 12 months93.9%

    England 91.0%

    6-in-1 complete primary course at 24 months92.8%

    England 92.2%

    MMR dose 1 at 24 months89.7%

    England 88.3%

    MMR dose 2 at age 590.7%

    England 82.8%

    4-in-1 pre-school booster at age 584.0%

    England 80.9%

    Sources & context

    QOF registers and review indicators; childhood immunisation coverage as supplied

    Powered by Coplug · Page 6 of 15
    07 / 15

    Early cancer diagnosis

    Early cancer diagnosis

    52.4%

    Lancashire and South Cumbria ICB, stage 1–2

    55.3%

    England, 2022

    75%

    National ambition by 2028

    ~2,010

    Extra early-stage cases a year to reach the ambition

    Stage 1–2 share by cancer type, 2022Lancashire and South Cumbria ICBEnglandNo usable stageStaged cancers
    Breast86.0%85.4%6%1,561
    Prostate42.4%53.2%11%1,404
    Lung31.1%33.8%15%1,374
    Bowel44.2%47.0%13%1,198
    Skin cancer86.1%87.8%21%519

    Across NHS Lancashire and South Cumbria ICB in 2022, 52.4% of cancers with a known stage (4,642 of 8,863) were diagnosed at stage 1 or 2, trailing England (55.3%) and 22.6 pp below the 75.0% national ambition by 2028. Known-stage completeness was 74.6% (8,863 of 11,883). Reaching the ambition requires about 2,010 extra early-stage cases annually across the ICB, where early-stage share fell 1.2 pp from 2013 to 2022. Locally, the cancer register grew 9.4% over 2023 to 2025 (England +9.0%) to 1,437 patients, while cervical screening fell 2.0% (England -1.0%) to 67.1%. These figures reflect ICB staging rather than PCN performance.

    Sources & context

    Stage at diagnosis: National Disease Registration Service

    Powered by Coplug · Page 7 of 15
    08 / 15

    Cancer waits, diagnostics and community services

    Cancer waits, diagnostics and community services

    Cancer waits and diagnostics, Jul 2026 (provisional)

    In July 2026 (provisional), East Lancashire Hospitals NHS Trust achieved 73.2% against the 85.0% cancer 62-day referral-to-treatment standard (11.8 pp below target), outperforming England (71.2%) but behind NHS Lancashire and South Cumbria Integrated Care Board (73.6%), Lancashire Teaching Hospitals NHS Foundation Trust (75.0%), and Northern Care Alliance NHS Foundation Trust (78.6%). On the 28-day faster diagnosis standard, East Lancashire Hospitals NHS Trust reached 81.5%, exceeding the 75.0% target by 6.5 pp, ahead of England (79.3%) and the ICB (78.4%), while Lancashire Teaching Hospitals NHS Foundation Trust reached 82.9%. Trust metrics reflect hospital performance, not PCN care.

    Pathways within standard (%)East LancashireLancashireNorthern Care AllianceLancashire and South Cumbria ICBEngland
    28-day faster diagnosis (75%)81.5082.9075.2078.3979.32
    31-day treatment (96%)98.1189.4394.5493.6292.50
    62-day referral to treatment (85%)73.1675.0478.6573.6271.16
    Diagnostic waits over 6 weeks (%)East LancashireLancashireNorthern Care AllianceEngland
    MRI0.432.415.0921.40
    CT0.1514.974.109.92
    Echocardiography0.0013.8531.4828.48
    Colonoscopy0.950.0040.0430.83
    Gastroscopy1.160.0036.4829.02
    All 15 DM01 tests3.2526.6515.7123.14
    Community services activityLancashire residentsLancashire and South Cumbria ICB
    Care contacts126,445193,720
    Referrals20,41529,855
    Patients with a contact47,32065,335

    Community services (residents of Lancashire), Jun 2026 (provisional). In June 2026 (provisional), community health service contacts for Hyndburn borough residents totaled 126,445, with 72,000 contacts involving adults aged 65 and over, representing a 56.9% share of all recorded contacts. These figures capture borough-level community activity rather than practice-level consultations, highlighting high service use among older residents across the wider local authority.

    Sources & context

    Waits and diagnostics: NHS England monthly statistics · ICB and provider data, not PCN

    Powered by Coplug · Page 8 of 15
    09 / 15

    Practice variation and patient experience

    Practice variation and patient experience

    In 2025/26, QOF vaccination achievement spans 79.4 pp, from 0.0% at Dill Hall Surgery to 79.4% at Dr Bello's Surgery, against 55.2% in England. Overall achievement ranges from 9.2% at Dill Hall Surgery to 94.6% at Great Harwood Medical Group (England 92.5%). Personalised care adjustments reach 12.1% at The Clayton Medical Ctr. (England 10.0%).

    GP Patient Survey by practice

    PracticeResponses% in IMD Q1Phone easyRequest led to apptOverall good
    Higher Heys9640.582.3%71.6%78.7%
    Great Harwood10432.239.9%61.8%77.5%
    King Street104100.075.5%71.1%65.5%
    Clayton Medical9745.640.5%57.8%65.5%
    Dr Bello's Surgery8881.265.1%74.3%64.1%
    Weavers11336.936.6%61.6%58.5%
    England—~2156.9%71.6%76.7%
    Sources & context

    QOF achievement; GP Patient Survey, practice-level results

    Powered by Coplug · Page 9 of 15
    11 / 15

    What the data can't tell us: gaps and local assets

    What the data can't tell us: gaps and local assets

    Local assets and voluntary sectorPCNHyndburnAssetPCNHyndburn
    Care homes (catchment)31 (629 beds)n/aSchools (catchment)40n/a
    Children's centres67Places of worship3755
    Libraries45Primary schools (LA maintained)1726
    Primary academies37

    0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.

    Sources & context

    Gaps are modelled estimates against benchmark rates; local assets as supplied

    Powered by Coplug · Page 11 of 15
    12 / 15

    Options for the PCN

    Options for the PCN

    Each option in full

    Option 1

    Standardised asthma review and recall

    Asthma 12-month reviews are 58.1% vs 65.7% in England (7.6 pp below) across 2,372 patients after falling 8.7% over 2023 to 2025 (England +4.4%), leaving 994 (about 990) unreviewed. For discussion: practices could run a single-template asthma recall combining annual reviews and smoking exposure checks. Moderate effort to run.

    Evidence base: the annual asthma review is the process gap between the register and outcomes.

    Policy anchor: Core20PLUS5 chronic respiratory disease priority.

    Option 2

    Secondary-prevention statin and formulary review

    In 2026, lipid-modifying drugs cost £1.90 per item across 80,012 items vs £1.64 in the ICB (£20,803 more), while statin therapy in diabetes with CVD is 81.1% (England 84.4%). For discussion: PCN pharmacists could review diabetes patients with CVD or QRISK ≥ 20% (62.6%) alongside practice formulary choices. Moderate effort to run.

    Evidence base: delivery measure for eight care processes and three treatment targets; shortfall here is what shows up later as emergency admission.

    Policy anchor: NHS Diabetes Prevention Programme and the eight care processes / three treatment targets.

    Option 3

    Non-frail diabetes HbA1c treatment intensification

    In 2024/25, diabetes without frailty achieving HbA1c <= 58 mmol/mol is 52.3% (916 of 1,750 patients) vs 57.4% in England (5.0 pp below) and 56.2% in the ICB (3.8 pp below). For discussion: practices could run a targeted recall and medicines intensification audit for non-frail diabetes patients above 58 mmol/mol. Moderate effort to run.

    Sources & context

    Options are the profile's; evidence base from Coplug's indicator catalogue

    Powered by Coplug · Page 12 of 15
    13 / 15

    Provenance and audit trail

    Provenance and audit trail

    Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

    RecommendationIndicator(s)Policy anchorData level
    Culturally tailored chronic disease recall (p2)Asian / Asian BritishNeighbourhood health framework · Core20PLUS5 approachPCN
    Two-track Core20 outreach (p3)Core20 cohort (IMD quintile 1)Core20PLUS5 · 10YHP equity testPCN
    SMI physical health check audit (p4)SMI register with a BMI recorded in the last 12 monthsMHIS · From Harm to HopePCN
    Hypertension case finding audit (p5)Hypertension: QOF prevalenceCore20PLUS5 CVD · CVDPREVENT 2029PCN
    Pre-school booster catch-up call-recall (p6)4-in-1 pre-school booster (DTaP/IPV) coverage at age 510YHP sickness to prevention · 95% targetPCN
    Cervical screening recall audit (p7)Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs)Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026PCN
    Option 1 · Standardised asthma review and recall (p12)Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Patients with Asthma (6-19 yrs): Second-hand smoking status recorded in the last 12 months (denominator incl. PCAs)Core20PLUS5 respiratoryPCN
    Option 2 · Secondary-prevention statin and formulary review (p12)Cost per item for Lipid-regulating drugs 2026 · Count of Items prescribed for Lipid-regulating drugs 2026 · Patients with diabetes and a history of CVD (excl. haem. stroke) treated with a statin (denominator incl. PCAs)NHS Long Term Plan (diabetes) and National Diabetes AuditPCN
    Option 3 · Non-frail diabetes HbA1c treatment intensification (p12)Diabetes without frailty: HbA1c at or below 58 mmol/mol · Diabetes with frailty: HbA1c at or below 75 mmol/mol · IFCC-HbA1c <= 58 mmol/mol in patients with diabetes without frailty (denominator incl. PCAs)—PCN
    Sources & context

    Re-run this profile in 12 months to see whether the gaps have narrowed

    Powered by Coplug · Page 13 of 15
    14 / 15

    Data sources

    Data sources

    Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

    DatasetLevelPeriodUsed for
    Coplug indicator tables: census, deprivation and QOF measuresPCN & Practice2023 to 2025, projected to 2030; 2023 to 2024Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12
    MHCLG, Rough sleeping snapshot in England: autumn 2025Local authorityAutumn 2025Pages 2, 4
    OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713)PCN2024/25Pages 2, 4
    OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002)Local authority2024/25; 2022-24Pages 2, 4
    ONS, Census 2021 TS039: provision of unpaid care (age-standardised)Local authorityCensus 2021Pages 2, 4
    QOF registers, prevalence and care processes (Coplug indicator tables)Practice2023 to 2025, projected to 2030Pages 4, 5, 6, 7, 8, 10
    UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26PCN & PracticeQ1 2025/26Pages 4, 6
    UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026ICB2025/26 season to 28 Feb 2026Pages 4, 6
    NHS England, Cancer Waiting Times: July 2026 monthly time series with revisionsICB & ProviderJul 2026 (provisional)Pages 7, 8
    NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental dataICB & Local authorityJun 2026 (provisional)Pages 7, 8
    NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026ProviderJul 2026Pages 7, 8
    National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022ICB2022Pages 7, 8
    NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted)PracticeSurvey Jan-Apr 2026Page 9
    NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domainPractice2025/26Page 9
    NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domainPractice2025/26Page 9
    Coplug indicator catalogue — definitions, cohorts, policy anchorsReferenceCurrentEvidence-base lines, page 13
    Sources & context

    Where a period is given as "as supplied", the source file did not state a vintage

    Powered by Coplug · Page 14 of 15
    15 / 15

    Methods, data-quality notes and limitations

    Methods, data-quality notes and limitations

    Methods

    Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.

    Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.

    Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.

    Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.

    Sources & context

    Estimates size the task; they are not confirmed missed patients

    Powered by Coplug · Page 15 of 15